Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
UNITED THERAPEUTICS Corp
Bear Case (25th pct.)
-33.6% vs price
Base Case (Median)
-14.6% vs price
Bull Case (75th pct.)
8.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $343.95 | -36.5% | High (40%) |
| PE Comparable | $626.71 | 15.7% | Medium (25%) |
| Growth Trajectory DCF | $846.88 | 56.3% | Medium (20%) |
| Graham Number | $323.43 | -40.3% | Medium (40%) |
| EV/EBITDA | $462.66 | -14.6% | Medium (20%) |
| EV/FCF | $548.81 | 1.3% | Medium (20%) |
| Earnings Power Value | $375.38 | -30.7% | Medium (50%) |
Based on 7 out of 7 methods, UTHR appears fairly valued at the current price of $541.70. The base case fair value of $462.66 implies 14.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.